Research Article | Published:

Replacement of renal function in uremic animals with a tissue-engineered kidney

Nature Biotechnology volume 17, pages 451455 (1999) | Download Citation

Subjects

Abstract

Current renal substitution therapy with hemodialysis or hemofiltration has been the only successful long-term ex vivo organ substitution therapy to date. Although this approach is life sustaining, it is still unacceptably suboptimal with poor clinical outcomes of patients with either chronic end-stage renal disease or acute renal failure. This current therapy utilizes synthetic membranes to substitute for the small solute clearance function of the renal glomerulus but does not replace the transport, metabolic, and endocrinologic functions of the tubular cells. The addition of tubule cell replacement therapy in a tissue-engineered bioartificial kidney comprising both biologic and synthetic components will likely optimize renal replacement to improve clinical outcomes. This report demonstrates that the combination of a synthetic hemofiltration device and a renal tubule cell therapy device containing porcine renal tubule cells in an extracorporeal perfusion circuit successfully replaces filtration, transport, metabolic, and endocrinologic functions of the kidney in acutely uremic dogs.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Cell therapy. Nature 392, 518– 524 (1998).

  2. 2.

    & Tissue engineering. Science 260, 920–926 (1993).

  3. 3.

    et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann. Surg. 225, 484–491 (1997).

  4. 4.

    et al. Treatment of diabetes by xenogeneic islets without immunosuppression. Use of a vascularized bioartificial pancreas. Diabetes 45, 342–347 (1996).

  5. 5.

    , , & Acute renal failure: growth factors, cell therapy, gene therapy. Proc. Assoc. Am. Physicians 109, 547– 557 (1997).

  6. 6.

    & Acute dialysis and continuous renal replacement: the emergence of new technology involving the nephrologist in the intensive care setting. Semin. Nephrol. 17, 306–320 (1997).

  7. 7.

    Therapeutic alternatives to renal replacement for critically ill patients in acute renal failure. Semin. Nephrol. 14, 64–82 (1994).

  8. 8.

    , , , & Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. J. Clin. Pharm.. 26, 686–689 (1986).

  9. 9.

    Excerpts from United States Renal Data System. Annual Data Report. Am.. J. Kidney Dis. 32(suppl 1), 569–580 (1998).

  10. 10.

    Acute renal failure: prevailing challenges and prospects for the future. Kidney Int. 48, S-26–S-32 (1995).

  11. 11.

    , , & The bioartificial renal tubule assist device to enhance CRRT in acute renal failure. Am. J. Kidney Dis. 30, S28– S31 (1997).

  12. 12.

    , , & Tissue engineering of a bioartificial renal tubule. ASAIO J. 44, 179–183 (1998).

  13. 13.

    , , & Tissue engineering of a bioartificial renal tubule assist device: in vitro transport and metabolic characteristics. Kidney Int. (In press).

  14. 14.

    , & Design engineering of a bioartificial renal tubule cell therapy device. Cell Transplant. (In press).

  15. 15.

    & Evolution of LDH isozymes during programmed cell death. Comp. Biochem. Physiol. 55, 161–166 (1976).

  16. 16.

    , , & Role of hydrostatic and oncotic pressures in renal sodium reabsorption. Circ. Res. 52, 491–500 (1983).

  17. 17.

    , & in The Kidney 5th edn (ed. Brenner, B.M.) 334–370 (W.B. Saunders, Philadelphia, 1996).

  18. 18.

    The renal regulation of acid base balance with special reference to the mechanism for acidifying the urine. I and II. Science 102,49–51, 81–85 (1945).

  19. 19.

    Regulation of renal ammoniagenesis in metabolic acidosis. Kidney Int. 40, 961–973 (1991).

  20. 20.

    Role of γ-glutamyltranspeptidase in the renal metabolism of glutathione. Miner. Electrolyte Metab. 9, 236– 245 (1983).

  21. 21.

    & in Renal Endocrinology . (ed. Dunn, M.J.) 114–141 (Williams & Wilkins, Baltimore, MD, 1983).

  22. 22.

    in Biomedical Engineering Handbook. (ed. Bronzino, J.) 1807– 1824 (CRC, 1995).

  23. 23.

    & Interaction between growth factors and retinoic acid in the induction of kidney tubulogenesis in tissue culture. Exp. Cell Res. 201, 8– 15 (1992).

  24. 24.

    , , & Tubulogenesis from isolated single cells of adult mammalian kidney: clonal analysis with a recombinant retrovirus. Am. J. Physiol. 271, F42–F49 (1996).

  25. 25.

    et al. Laminin—a glycoprotein from basement membranes. J. Biol. Chem. 254, 9933–9937 (1979).

  26. 26.

    et al. Immunoprotection provided by the bioartificial pancreas in a xenogeneic host. Trans. Proc. 29, 2116– 2117 (1997).

  27. 27.

    Renal excretion of acid. Fed. Proc. 7, 418 –426 (1948).

  28. 28.

    & The generation of transgenic pigs as potential organ donors for humans. Nat. Med. 1, 965–966 (1995).

Download references

Acknowledgements

This work was supported by National Institutes of Health Grants DK-39255, DK-48175, and DK-50539, the VA Research Service, and Nephros Therapeutics. The expert technical assistance of Annie Browning and Anand Gupte, along with the excellent secretarial support of Donna Hall, is appreciated

Author information

Affiliations

  1. Department of Internal Medicine, University of Michigan, and Department of Internal Medicine, VA Medical Center, Ann Arbor , MI 48109.

    • H. David Humes
    • , Deborah A. Buffington
    • , Sherrill M. MacKay
    • , Angela J. Funke
    •  & William F. Weitzel

Authors

  1. Search for H. David Humes in:

  2. Search for Deborah A. Buffington in:

  3. Search for Sherrill M. MacKay in:

  4. Search for Angela J. Funke in:

  5. Search for William F. Weitzel in:

Corresponding author

Correspondence to H. David Humes.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/8626

Further reading